The report was produced by leading DILI experts from drug regulation, industry and research globally. DILI is a growing challenge because of the ever-increasing number of products used in medical care. DILI is rare but can be serious and is largely unpredictable. The CIOMS consensus report provides a critical framework and essential set of tools to detect, diagnose and manage DILI during drug development and post-marketing.
Several number of COST Action 17-112 PRO-EURO DILI NETWORK members contributed to it.
The report in PDF format is freely available here: